

Supporting Information

Pd-Catalyzed Cross-Coupling of Highly Sterically Congested Enol Carbamates with Grignard Reagents *via* C-O Bond Activation

Zicong Chen,^[a] and Chau Ming So^{*[a, b]}

[a] *State Key Laboratory of Chemical Biology and Drug Discovery and Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong*

[b] *The Hong Kong Polytechnic University, Shenzhen Research Institute, Shenzhen, People's Republic of China*

E-mail: chau.ming.so@polyu.edu.hk

Table of Contents

1. General considerations.....	2
2. Procedure and results of specific experiments.....	3
3. The preparation of enol carbamate substrates.....	8
4. General procedures for condition optimization and scope	12
5. Data of ligand screening	14
6. Characterization of products	17
7. ¹ H, ¹³ C, ¹⁹ F-NMR and HRMS spectra	35
8. References.....	135




1. General considerations

Unless otherwise noted, all reagents were purchased from commercial suppliers and used without purification. All Pd-catalyzed cross-coupling reactions were performed in resealable screw cap Schlenk tube (approx. 10 mL volume) in the presence of Teflon-coated magnetic stir bar (5 mm×10 mm). Solvents were distilled following the standard procedures under nitrogen.¹ Most of the Grignard reagents were purchased from Energy. Others were prepared according to the general procedures² and titrated according to reported methods.³ Thin layer chromatography was performed on pre-coated silica gel 60 F₂₅₄ plates. Silica gel (Merck, 70-230 and 230-400 mesh) was used for column chromatography. Melting points were recorded on an uncorrected Büchi Melting Point B-545 instrument. NMR spectra were recorded on a Bruker spectrometer (400 MHz for ¹H, 100 MHz for ¹³C, 376 MHz for ¹⁹F and 162 MHz for ³¹P). Spectra were referenced internally to the residual proton resonance in CDCl₃ (δ 7.26 ppm) as the internal standard. Chemical shifts (δ) were reported as part per million (ppm) in δ scale downfield from TMS. ¹³C NMR spectra were referenced to CDCl₃ (δ 77.0 ppm, the middle peak). ¹⁹F NMR chemical shifts were determined relative to CFCl₃ as the external standard and low field is positive. ³¹P NMR spectra were referenced to 85% H₃PO₄ externally. Coupling constants (*J*) were reported in Hertz (Hz). Mass spectra (EI-MS and ESI-MS) were recorded on a HP 5989B Mass Spectrometer. High-resolution mass spectra (HRMS) were obtained on a Bruker APEX 47e FTICR mass spectrometer (ESI-MS and APPI-MS). GC-MS analysis was conducted on a HP 5973 GCD system using a HP5MS column (30 m × 0.25 mm). The products described in GC yield were accorded to the authentic samples/dodecane calibration standard from HP 6890 GC-FID system. All yields reported refer to isolated yield of compounds estimated to be greater than 95% purity as determined by capillary gas chromatography (GC) or ¹H NMR. Compounds described in the literature were characterized by comparison of their ¹H, ¹³C and/or ¹⁹F NMR spectra to the previously reported data. The procedures in this section are representative, and thus the yields may differ from those reported in tables. In case of new and uncharacterized compounds, *Z/E*-configurations were determined by NOESY experiments recorded on a JEOL JNM-ECZ500R/S1 spectrometer.



2. Procedure and results of specific experiments



2.1 Thermal decomposition experiments



Compound cyclohex-1-en-1-yl pivalate⁴ (0.20 mmol), cyclohex-1-en-1-yl 4-methylbenzenesulfonate⁵ (0.20 mmol) and cyclohex-1-en-1-yl dimethylcarbamate⁶ (0.20 mmol) were added and sealed in Schlenk tubes separately. The tubes were then put in the pre-heated oil bath (100 °C) for 16 h. After cooled down to room temperature, the tubes were separately added with dioxane (0.20 mmol) as internal standard. Then the mixtures were dissolved by CDCl₃ (1.0 mL) separately to perform ¹H NMR detection (the spectra are attached below).



^1H NMR spectra of decomposition experiments (dioxane as internal standard):








2.2 Selective cross-coupling of 2-oxo-2*H*-chromen-4-yl dimethylcarbamate (4b)

Experimental procedure:

A Schlenk tube was evacuated and flushed with nitrogen (3 cycles). To this tube was charged ZnCl₂ (0.40 mmol, in THF) by syringe, and the solution was stirred at 0 °C. Then *p*-tolylmagnesium bromide (0.80 mmol, in THF) was added dropwise by syringe while stirring. The mixture was stirred at room temperature for 30 min to give di-*p*-tolylzinc reagent.

To another separate Schlenk tube were charged Pd(OAc)₂ (1.8mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-2-yl dimethylcarbamate **4f** (21.7 mg, 0.10 mmol) and 2-oxo-2*H*-chromen-4-yl dimethylcarbamate **4b** (23.3 mg, 0.10 mmol). The tube was evacuated and flushed with nitrogen (3 cycles). Distilled THF (0.40 mL) was added to the tube by syringe followed by the addition of the freshly prepared di-*p*-tolylzinc reagent. The mixture was stirred for 16 h. After the reaction time, the mixture was quenched with water and extracted with EA. The organic layer was extracted and then subjected to GCMS analysis and column chromatography to give the product.




Reaction conditions and results:


Entry	Reaction Temperature	Yield (6g)	Yield (6o)
1	r.t.	98%	0%
2	50 °C	77%	0%

3. The preparation of enol carbamate substrates

Known enol carbamates (**1a**⁶, **1c**⁶, **4b**⁶, **4c**⁷, **4e**⁶, **4f**⁶) were synthesized according to the reported procedure.




6,7-Dihydro-5H-benzo[7]annulen-9-yl dimethylcarbamate (**1b**)



Compound 6,7-Dihydro-5H-benzo[7]annulen-9-yl dimethylcarbamate **1b** was synthesized by modifying a previous procedure.⁸ In a 250 mL round-bottomed flask under magnetic stirring and nitrogen atmosphere was added 6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (1.60 g, 10.0 mmol) in THF (30 mL). The reaction mixture was cooled to -20 °C. Sodium *tert*-butoxide (1.15 g, 12.0 mmol) was added in one portion. The solution was stirred at -20 °C to -5 °C for 1 h then at room temperature for 30 min. When the solution was again cooled to -20 °C, *N,N*-dimethylcarbamoyl chloride (1.30 g, 12.1 mmol) was added in one portion. The resulting solution was stirred at -20 to -5 °C for 6 h, quenched with water (20 mL) and then the mixture was extracted three times with EtOAc. The combined organic layer was washed with water and brine, dried over Na_2SO_4 . The residue was purified by flash silica-gel column chromatography to afford the product **1b** as a pink solid (1.86 g, 80%), M.P.: 82.5–83.7 °C, R_f = 0.2 (EA/Hexane = 1 : 20). ¹H NMR (400 MHz, CDCl_3) δ 2.08–2.15 (m, 4H), 2.85 (t, J = 5.6 Hz, 2H), 2.94 (s, 3H), 3.12 (s, 3H), 5.87 (t, J = 6.1 Hz, 1H), 7.19–7.24 (m, 3H), 7.28–7.31 (m, 1H); ¹³C NMR (100 MHz, CDCl_3) δ 24.9, 31.6, 33.5, 36.3,


36.5, 119.2, 125.3, 125.9, 127.9, 129.1, 135.1, 141.8, 146.3, 155.4. HRMS (ESI): calcd. for : $C_{14}H_{17}NO_2Na^+$ $[M + Na]^+$: 254.1151, found 254.1158.

(Z)-1-phenylprop-1-en-1-yl dimethylcarbamate (1d)



In a 250 mL round-bottomed flask under magnetic stirring and nitrogen atmosphere was added propiophenone (1.30 g, 9.70 mmol) in THF (30 mL). The reaction mixture was cooled to -20 °C. Sodium *tert*-butoxide (1.10 g, 11.6 mmol) was added in one portion. The solution was stirred at -20 °C to -5 °C for 1 h then at room temperature for 30 min. When the solution was again cooled to -20 °C, *N,N*-dimethylcarbamoyl chloride (1.30 g, 12.1 mmol) was added in one portion. The resulting solution was stirred at -20 to -5 °C for 6 h, quenched with water (20 mL) and then the mixture was extracted three times with EtOAc. The combined organic layer was washed with water and brine, dried over Na_2SO_4 . The residue was purified by flash silica-gel column chromatography to afford the product **1d** as colorless liquid (1.16 g, 57%), R_f = 0.2 (EA/Hexane = 1 : 20). 1H NMR (400 MHz, $CDCl_3$) δ 1.78 (d, J = 7.0 Hz, 3H), 3.01 (s, 3H), 3.17 (s, 3H), 5.89 (q, J = 7.0 Hz, 1H), 7.26–7.44 (m, 5H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 11.3, 36.3, 36.7, 112.5, 124.2, 127.7, 128.3, 135.8, 147.2, 154.1. HRMS (ESI): calcd. for: $C_{12}H_{15}NO_2Na^+$ $[M + Na]^+$: 228.0995, found 228.1001.


2-(Naphthalen-2-yl)cyclohex-1-en-1-yl dimethylcarbamate (4a)



In a 250 mL round-bottomed flask was added 2-(naphthalen-2-yl)cyclohexan-1-one (1.70 g, 7.60 mmol). The flask was evacuated and flushed with nitrogen (3 cycles) and THF (30 mL) was added. The reaction mixture was cooled to -20 °C. Sodium *tert*-butoxide (0.88 g, 9.10 mmol) was added in one portion. The solution was stirred at -20 °C to -5 °C for 1 h then at room temperature for 30 min. When the solution was again cooled to -20 °C, *N,N*-dimethylcarbamoyl chloride (0.98 g, 9.10 mmol) was added in one portion. The resulting solution was stirred at -20 to -5 °C for 6 h, quenched with water (20 mL) and then the mixture was extracted three times with EtOAc. The combined organic layer was washed with


water and brine, dried over Na_2SO_4 . The residue was purified by flash silica-gel column chromatography to afford the product **4a** as a white solid (1.40 g, 62%), M.P.: 71.5–73.6 °C, $R_f = 0.2$ (EA/Hexane = 1:20). ^1H NMR (400 MHz, CDCl_3) δ 1.84–1.90 (m, 4H), 2.42 (t, $J = 6.2$ Hz, 2H), 2.54 (t, $J = 5.6$ Hz, 2H), 2.71 (s, 3H), 2.82 (s, 3H), 7.44–7.47 (m, 3H), 7.76–7.83 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 22.8, 23.0, 28.1, 30.1, 36.1, 36.3, 124.6, 125.4, 125.7, 126.3, 126.6, 127.1, 127.4, 127.8, 132.2, 133.2, 137.0, 144.4, 154.7. HRMS (ESI): calcd. for: $\text{C}_{19}\text{H}_{22}\text{NO}_2^+ [\text{M} + \text{H}]^+$: 296.1645, found 296.1653.

Cyclohept-1-en-1-yl dimethylcarbamate (**4d**)



In a 250 mL round-bottomed flask under magnetic stirring and nitrogen atmosphere was added cycloheptanone (1.70 g, 15.2 mmol) in THF (30 mL). The reaction mixture was cooled to -20 °C. Sodium *tert*-butoxide (1.80 g, 18.2 mmol) was added in one portion. The solution was stirred at -20 °C to -5 °C for 1 h then at room temperature for 30 min. When the solution was again cooled to -20 °C, *N,N*-dimethylcarbamoyl chloride (1.90 g, 18.2 mmol) was added in one portion. The resulting solution was stirred at -20 to -5 °C for 6 h, quenched with water (20 mL) and then the mixture was extracted three times with EtOAc. The combined organic layer was washed with water and brine, dried over Na_2SO_4 . The residue was purified by flash silica-gel column chromatography to afford the product **4d** as colorless liquid (0.57 g, 21%), $R_f = 0.2$ (EA/Hexane = 1:20). ^1H NMR (400 MHz, CDCl_3) δ 1.57–1.62 (m, 2H), 1.65–1.74 (m, 4H), 2.09 (q, $J = 6.4$ Hz, 2H), 2.33 (t, $J = 4.5$ Hz, 2H), 2.93 (s, 6H), 5.47 (t, $J = 6.5$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.1, 25.3, 27.0, 31.1, 33.3, 36.2, 117.4, 153.5, 155.4. HRMS (ESI): calcd. for: $\text{C}_{10}\text{H}_{17}\text{NO}_2\text{Na}^+ [\text{M} + \text{Na}]^+$: 206.1151, found 206.1156.


Procedures for the preparation of compound **10a** and **10b**:



To a 20 mL dry flask was added sodium hydride (60% w/w dispersion in mineral oil; 80.0 mg,


2.00 mmol) followed by the addition of DMF (5 mL). The reaction mixture was stirred at r.t. under nitrogen atmosphere. 1,2-Diphenylbutan-1-one (224 mg, 1.00 mmol) was added in 2 portions. The mixture was stirred at room temperature till the H₂ release ceased, then the mixture was stirred at 75 °C for 30 min. Then the mixture was allowed to cool down to room temperature and *N,N*-dimethylcarbamoyl chloride (323 mg, 3.00 mmol) was added dropwise. The resulting mixture was stirred at room temperature overnight. The mixture was quenched with water and then the mixture was extracted three times with EtOAc. The combined organic layer was washed with water and brine, dried over Na₂SO₄. The residue was purified by flash silica-gel column chromatography (Hexane: EA = 50:1~20:1) to give the two isomers (64% yield; **10a** + **10b**).

(Z)-1,2-diphenylbut-1-en-1-yl dimethylcarbamate (10a)



White solid (131 mg, 44%), M.P.: 95.2–96.5 °C, *R*_f = 0.7 (EA/Hexane = 1 : 4). ¹H NMR (400 MHz, CDCl₃) δ 0.97 (t, *J* = 7.4 Hz, 3H), 2.48 (q, *J* = 7.4 Hz, 2H), 2.64 (s, 3H), 2.73 (s, 3H), 7.25–7.28 (m, 1H), 7.31–7.40 (m, 7H), 7.51–7.53 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 13.1, 26.2, 36.0, 36.4, 126.7, 127.8, 128.0, 128.1, 128.3, 128.6, 132.0, 136.3, 138.9, 142.5, 154.9. The configuration was determined by NOESY. HRMS (APPI): calcd. for: C₁₉H₂₂NO₂⁺ [*M* + *H*]⁺: 296.1645, found 296.1647.

(E)-1,2-diphenylbut-1-en-1-yl dimethylcarbamate (10b)



White solid (60.0 mg, 20%), M.P.: 68.7–71.3 °C, *R*_f = 0.65 (EA : Hexane = 1 : 4). ¹H NMR (400 MHz, CDCl₃) 1.00 (t, *J* = 7.5 Hz, 3H), 2.56 (q, *J* = 7.5 Hz, 2H), 2.95 (s, 3H), 3.15 (s, 3H), 7.08–7.22 (m, 10H); ¹³C NMR (100 MHz, CDCl₃) δ 12.2, 26.1, 36.3, 36.6, 126.6, 127.2, 127.6, 128.0, 129.6, 132.8, 136.1, 139.5, 143.0, 154.6. The configuration was determined by NOESY. HRMS (APPI): calcd. for: C₁₉H₂₂NO₂⁺ [*M* + *H*]⁺: 296.1645, found 296.1646.

4. General procedures for condition optimization and scope

4.1 General procedures for ligand screening (GP1)

An array of Schlenk tubes were charged with Teflon-coated magnetic stir bar (5 mm × 10 mm), Pd(OAc)₂ (1.8 mg, 4 mol%), ligands (8 mol%), and then were evacuated and flushed with nitrogen (3 cycles). 3,4-Dihydronaphthalen-1-yl dimethylcarbamate (0.20 mmol), the freshly distilled THF (0.40 mL) and mesitylmagnesium bromide (0.40 mmol, in THF) were added by syringes to the array of Schlenk tubes respectively. The batch of Schlenk tubes were sealed and magnetically stirred in a preheated oil bath at 50 °C for 1 h. When cooled down to room temperature, ethyl acetate (~4 mL), dodecane (45.2 µL, internal standard) and water (~2 mL) were added. The organic layer after extraction was subjected to GC analysis. The GC yield was previously calibrated by authentic sample/dodecane calibration curve.

4.2 General procedures for condition optimization (GP2)

Stock solutions of Pd(OAc)₂ and IPr•HCl (Pd/L = 1:2) in freshly distilled THF were first prepared under N₂. The concentrations were solution A (1 mol% of Pd / 0.40 mL) and solution B (2 mol% of Pd / 0.40 mL) respectively. For those entries using 4 mol% of Pd, Pd(OAc)₂ and ligands were added directly as solids. An array of Schlenk tubes were charged with Teflon-coated magnetic stir bar (5 mm × 10 mm), and equipped with screw cap. After the addition of solid materials, the tubes were evacuated and flushed with nitrogen (3 cycles). The Schlenk tubes were then added with 3,4-dihydronaphthalen-1-yl dimethylcarbamate (0.20 mmol) via micro-syringe. The stock solutions (if applicable) and mesitylmagnesium bromide (0.40 mmol, in THF) were added by syringes to the array of Schlenk tubes respectively. The batch of Schlenk tubes were sealed and magnetically stirred under certain conditions (detailed conditions were indicated in the manuscript). After cooled down to room temperature, ethyl acetate (~4 mL), dodecane (45.2 µL, internal standard) and water (~2 mL) were added. The organic layer was subjected to GC analysis. The GC yield was previously calibrated by authentic sample/dodecane calibration curve.


4.3 General procedures for the entries of the scope (GP3)

A Schlenk tube was charged with Teflon-coated magnetic stir bar (5 mm × 10 mm), Pd(OAc)₂ (1.8 mg, 4 mol%), ligand (8 mol%) and enol carbamate (if solid) (0.20 mmol).









Then the tube was evacuated and flushed with nitrogen (3 cycles). Enol carbamate (if liquid) (0.20 mmol) was added. Freshly distilled THF (0.40 mL) and followed by Grignard reagent (0.40 mmol, in THF) were added to the tube via syringes. The Schlenk tube was sealed and magnetically stirred at an indicated temperature and time. When cooled down to room temperature, ethyl acetate (~4 mL) and water (~2 mL) were added. The organic layer after extraction was combined. After removing the solvent, the residue was subjected to column chromatography isolation to afford the corresponding product.






5. Data of ligand screening

Table S5. Initial screening of ligands^a



Entry	Ligand		Yield (3a)
1	1,3-Di- <i>i</i> -propylimidazolium chloride		trace
2	1,3-Dicyclohexylimidazolium chloride		7%
3	1,3-Bis(2,4,6-trimethylphenyl)imidazolinium chloride (IMes•HCl)		80%
4	1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazolium tetrafluoroborate		60%
5	1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazolium chloride		90%
6	1,3-Bis(2,6-diisopropylphenyl)imidazolium Chloride (IPr•HCl)		98%
7	1,3-Bis(2,6-di- <i>i</i> -propylphenyl)-4,5-dihydroimidazolium tetrafluoroborate		11%


8	1,3-Bis(2,6-di- <i>i</i> -propylphenyl)-4,5-dihydroimidazolium chloride		trace
9	1,3-Di- <i>t</i> -butylimidazolium chloride		trace
10	1,3-Bis(1-adamantyl)imidazolium chloride		trace
11	1,3-Bis(1-adamantyl)benzimidazolium chloride		trace
12	Triphenylphosphine	PPh ₃	14%
13	Tricyclohexylphosphine	PCy ₃	27%
14	Dicyclohexyl(2',6'-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (SPhos)		28%
15	Dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (XPhos)		23%
16	Dicyclohexyl(2',4',6'-triisopropyl-3,6-dimethoxy-[1,1'-biphenyl]-2-yl)phosphine (BrettPhos)		26%
17	2-(2-(Dicyclohexylphosphino)phenyl)-1-methyl-1 <i>H</i> -indole (CM-Phos)		trace

18	2-(Dicyclohexylphosphino)-1-phenylindole (cataCXium®PinCy)		trace
19	2-(Dicyclohexylphosphino)-1-phenyl-1 <i>H</i> -pyrrole (cataCXium®PCy)		trace
20	Butyldi-1-adamantylphosphine (cataCXium®A)		trace
21	Benzyl-di-1-adamantylphosphine (cataCXium®ABn)		6%
22	<i>N</i> -[2-(Di-1-adamantylphosphino)phenyl]morpholine (MorDalPhos)		20%

^aReaction conditions: **1a** (0.20 mmol), **2a** (0.40 mmol), THF (totally around 1 mL), Pd(OAc)₂ (4 mol%), Ligand (8 mol%), under N₂ at 50 °C for 1 h; calibrated GC–FID yields are reported using dodecane as internal standard.

6. Characterization of products

4-Mesityl-1,2-dihydronaphthalene (Scheme 2, compound 3a)




Compound **3a** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IPr•HCl (6.8 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and mesitylmagnesium bromide (0.40 mmol, in THF) were used.

Colorless liquid (46 mg, 93%). Eluents (R_f = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.12 (s, 6H), 2.35 (s, 3H), 2.44–2.49 (m, 2H), 2.91–2.95 (m, 2H), 5.86 (t, J = 4.5 Hz, 1H), 6.57–6.58 (m, 1H), 6.93–6.96 (m, 2H), 7.02–7.05 (m, 1H), 7.12–7.16 (m, 1H), 7.19–7.21 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 19.9, 21.0, 23.4, 28.2, 124.0, 126.5, 126.8, 127.4, 127.5, 128.0, 134.8, 136.1, 136.3, 136.7, 137.5. HRMS (APPI): calcd. for C₁₉H₂₀: 248.1565, found 248.1561.


For the synthesis of compound **3a** of 1 mmol scale:

A Schlenk tube was charged with Teflon-coated magnetic stir bar, Pd(OAc)₂ (8.9 mg, 4 mol%) and IPr•HCl (34.0 mg, 8 mol%). Then the tube was evacuated and flushed with nitrogen (3 cycles). 3,4-Dihydronaphthalen-1-yl dimethylcarbamate (217 mg, 1.00 mmol) was added. Freshly distilled THF (1.30 mL) and followed by Grignard reagent (2.00 mmol, 0.74 M in THF) were added to the tube via syringe. The Schlenk tube was sealed and magnetically stirred at 50 °C for 4 h. When cooled down to room temperature, water was added and the mixture was extracted by ethyl acetate. The organic layer after extraction was combined. After removing the solvent, the residue was subjected to column chromatography isolation to afford **3a** (0.24 g, 96%).

2'-Methyl-3,4-dihydro-1,1'-binaphthalene (Scheme 2, compound 3b)⁹

Compound **3b** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IPr•HCl (6.8 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (46.3 mg, 0.20 mmol) and (2-methylnaphthalen-1-yl)magnesium bromide (0.40 mmol, in THF) were used.


White solid (52 mg, 96%). Eluents (R_f = 0.4, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.37 (s, 3H), 2.58–2.64 (m, 2H), 3.05–3.10 (m, 2H), 6.03 (t, J = 4.5 Hz, 1H), 6.47 (d, J = 7.6 Hz, 1H), 6.95–6.99 (m, 1H), 7.14–7.18 (m, 1H), 7.26–7.28 (m, 1H), 7.36–7.46 (m, 3H), 7.80–7.82 (m, 2H), 7.86–7.88 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.2, 23.5, 28.2, 124.7, 124.7, 125.8, 126.0, 126.5, 126.9, 127.1, 127.5, 127.8, 128.6, 129.1, 132.1, 133.1, 133.8, 135.1, 135.9, 136.1, 136.6.

9-Mesityl-6,7-dihydro-5H-benzo[7]annulene (Scheme 2, compound 3c)

Compound **3c** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IPr•HCl (6.8 mg, 8 mol%), 6,7-dihydro-5H-benzo[7]annulen-9-yl dimethylcarbamate (46.3 mg, 0.20 mmol) and mesitylmagnesium bromide (0.40 mmol, in THF) were used.


White solid (45 mg, 86%). M.P.: 83.9–86.5 °C. Eluents (R_f = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.14 (s, 6H), 2.16–2.19 (m, 2H), 2.23–2.30 (m, 2H), 2.33 (s, 3H), 2.82–2.85 (m, 2H), 6.02 (t, J = 6.5 Hz, 1H), 6.74–6.76 (m, 1H), 6.90–6.93 (m, 2H), 7.07–7.11 (m, 1H), 7.13–7.17 (m, 1H), 7.24–7.26 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.4, 21.0, 26.2, 33.5, 34.7, 125.9, 126.5, 127.6, 128.2, 128.9, 131.2, 136.1, 136.6, 140.0, 140.3, 140.7, 141.8. HRMS (APPI): calcd. for C₂₀H₂₂: 262.1722, found

262.1717.

9-(2,6-Dimethylphenyl)-6,7-dihydro-5H-benzo[7]annulene (Scheme 2, compound 3d)


Compound **3d** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IPr•HCl (6.8 mg, 8 mol%), 6,7-dihydro-5H-benzo[7]annulen-9-yl dimethylcarbamate (46.3 mg, 0.20 mmol) and (2,6-dimethylphenyl)magnesium bromide bromide (0.40 mmol, in THF) were used.

White solid (36 mg, 72%). M.P.: 118.8–121.9 °C. Eluents (*R_f* = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.17–2.21 (m, 8H), 2.24–2.30 (m, 2H), 2.83–2.86 (m, 2H), 6.02 (t, *J* = 6.5 Hz, 1H), 6.72–6.74 (m, 1H), 7.07–7.18 (m, 5H), 7.24–7.26 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.4, 26.4, 33.6, 34.5, 125.9, 126.6, 126.6, 127.4, 127.6, 129.0, 131.2, 136.7, 139.7, 140.7, 141.8, 143.1. HRMS (APPI): calcd. for C₁₉H₂₀: 248.1565, found 248.1559.

(Z)-(1-(2-methoxyphenyl)ethene-1,2-diyl)dibenzene (Scheme 2, compound 3e)


Compound **3e** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1,2-diphenylvinyl dimethylcarbamate (53.5 mg, 0.20 mmol) and (2-methoxyphenyl)magnesium bromide (0.40 mmol, in THF) were used.

White solid (55 mg, 96%). M.P.: 64.9–66.3 °C. Eluents (*R_f* = 0.5, Hexane/EA = 30:1) was used for flash column chromatography. GCMS indicated > 99:1 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 3.65 (s, 3H), 6.96–6.70 (m, 2H), 7.05–7.17 (m, 7H), 7.26–7.40 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 55.6, 111.6, 121.1, 126.5, 126.7, 127.2, 127.9, 128.1, 128.8, 128.9, 129.0, 129.2, 131.6, 137.6, 138.9, 142.8, 157.5. HRMS (APPI): calcd. for C₂₁H₁₈O: 286.1358, found 286.1353.

(Z)-(1-(*o*-tolyl)ethene-1,2-diyl)dibenzene (Scheme 2, compound 3f)¹⁰


Compound **3f** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1,2-diphenylvinyl dimethylcarbamate (53.5 mg, 0.20 mmol) and *o*-tolylmagnesium bromide (0.40 mmol, in THF) were used.

White solid (51 mg, 94%). Eluents (*R*_f = 0.3, Hexane) was used for flash column chromatography. GCMS indicated > 99:1 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 2.07 (s, 3H), 6.97–6.99 (m, 2H), 7.10 (s, 1H), 7.11–7.16 (m, 4H), 7.23–7.36 (m, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 19.6, 126.3, 126.6, 126.9, 127.3, 127.6, 128.1, 128.2, 128.3, 129.0, 130.2, 130.5, 136.6, 137.3, 139.6, 141.4, 142.3.

(Z)-(1-Mesitylethene-1,2-diyl)dibenzene (Scheme 2, compound 3g)¹¹


Compound **3g** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1,2-diphenylvinyl dimethylcarbamate (53.5 mg, 0.20 mmol) and mesitylmagnesium bromide (0.40 mmol, in THF) were used.

White solid (57 mg, 95%). M.P.: 135.3–137.7 °C. Eluents (*R*_f = 0.4, Hexane) was used for flash column chromatography. GCMS indicated > 99:1 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 2.04 (s, 6H), 2.38 (s, 3H), 6.96–7.00 (m, 4H), 7.13–7.18 (m, 4H), 7.25–7.38 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 19.8, 21.2, 126.0, 126.9, 127.3, 128.1, 128.2, 128.4, 128.7, 135.9, 136.0, 136.9, 137.5, 139.8, 141.5. HRMS (APPI): calcd. for C₂₃H₂₂: 298.1722, found 298.1717.

(Z)-1-(1,2-diphenylvinyl)-2-methylnaphthalene (Scheme 2, compound 3h)


Compound **3h** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1,2-diphenylvinyl dimethylcarbamate (53.5 mg, 0.20 mmol) and (2-methylnaphthalen-1-yl)magnesium bromide (0.40 mmol, in THF) were used.

Colorless liquid (60 mg, 94%). Eluents (*R*_f = 0.35, Hexane) was used for flash column chromatography. GCMS indicated 98:2 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 2.24 (s, 3H), 6.85–6.87 (m, 2H), 7.00–7.04 (m, 3H), 7.24–7.42 (m, 9H), 7.81–7.87 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 20.1, 125.0, 125.7, 126.2, 126.4, 127.0, 127.4, 127.7, 128.0, 128.1, 128.5, 128.5, 129.0, 129.7, 132.1, 132.4, 133.6, 135.5, 137.1, 138.6, 141.8. HRMS (APPI): calcd. for C₂₅H₂₀: 320.1565, found 320.1561.


(Z)-1-methyl-2-(1-phenylprop-1-en-1-yl)benzene (Scheme 2, compound 3i)¹²

Compound **3i** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1-phenylprop-1-en-1-yl dimethylcarbamate (41.1 mg, 0.20 mmol) and *o*-tolylmagnesium bromide (0.40 mmol, in THF) were used.


Colorless liquid (32 mg, 77%). Eluents (*R*_f = 0.45, Hexane) was used for flash column chromatography. GCMS indicated > 99:1 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 1.66 (d, *J* = 6.9 Hz, 3H), 2.14 (s, 3H), 6.33–6.39 (m, 1H), 7.14–7.15 (m, 1H), 7.23–7.32 (m, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 15.4, 19.5, 123.8, 125.7, 126.0, 126.6, 127.1, 128.2, 130.0, 130.1, 136.6, 139.2, 141.4, 141.5.

(Z)-9-(1-phenylprop-1-en-1-yl)phenanthrene (Scheme 2, compound 3j)

Compound **3j** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1-phenylprop-1-en-1-yl dimethylcarbamate (41.1 mg, 0.20 mmol) and phenanthren-9-ylmagnesium bromide (0.40 mmol, in THF) were used. White solid (32 mg, 54%). M.P.: 141.5–143.6 °C. Eluents (*R_f* = 0.4, Hexane/DCM = 19:1) was used for flash column chromatography. GCMS indicated 94:6 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 1.68 (d, *J* = 6.9 Hz, 3H), 6.64 (q, *J* = 6.9 Hz, 1H), 7.19–7.27 (m, 3H), 7.35–7.37 (m, 2H), 7.50–7.54 (m, 1H), 7.63–7.72 (m, 4H), 7.90–7.92 (m, 2H), 8.76–8.80 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 15.8, 122.6, 122.8, 125.8, 126.1, 126.4, 126.5, 126.7, 126.7, 126.8, 128.0, 128.3, 128.5, 130.1, 130.6, 131.2, 131.8, 136.1, 140.3, 141.7. HRMS (APPI): calcd. for C₂₃H₁₈: 294.1409, found 294.1404.


4-(*o*-Tolyl)-1,2-dihydronaphthalene (Scheme 3, compound 6a)¹³

Compound **6a** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and *o*-tolylmagnesium bromide (0.40 mmol, in THF) were used. Colorless liquid (40 mg, 91%). Eluents (*R_f* = 0.4, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.16 (s, 3H), 2.45–2.51 (m, 2H), 2.91–2.98 (m, 2H), 5.99 (t, *J* = 4.5 Hz, 1H), 6.68 (d, *J* = 7.5 Hz, 1H), 7.07–7.11 (m, 1H), 7.15–7.19 (m, 1H), 7.22–7.32 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 19.8, 23.4, 28.1, 124.8, 125.7, 126.4, 126.8, 127.2, 127.4, 127.6, 129.8, 130.0, 135.2, 135.8, 136.5, 139.4, 140.4.

9-(3-Fluorophenyl)-6,7-dihydro-5H-benzo[7]annulene (Scheme 3, compound 6b)

Compound **6b** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 6,7-dihydro-5H-benzo[7]annulen-9-yl dimethylcarbamate (46.3 mg, 0.20 mmol) and (3-fluorophenyl)magnesium bromide (0.40 mmol, in THF) were used.

Colorless liquid (45 mg, 94%). Eluents (R_f = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 1.97–2.02 (m, 2H), 2.16–2.23 (m, 2H), 2.65–2.68 (m, 2H), 6.49 (t, J = 7.4 Hz, 1H), 6.94–7.07 (m, 4H), 7.19–7.30 (m, 4H); ¹⁹F NMR (376 MHz, CDCl₃) δ –113.9; ¹³C NMR (100 MHz, CDCl₃) δ 25.3, 32.3, 35.1, 113.7 (d, J = 21.2 Hz), 114.7 (d, J = 21.5 Hz), 123.6 (d, J = 2.5 Hz), 125.9, 127.3, 128.6, 129.1, 129.4, 129.4 (d, J = 8.5 Hz), 139.6, 142.0, 142.1, 144.6 (d, J = 7.5 Hz), 162.8 (d, J = 243.4 Hz). HRMS (APPI): calcd. for C₁₇H₁₅F: 238.1158, found 238.1151.


9-(2-Methoxyphenyl)-6,7-dihydro-5H-benzo[7]annulene (Scheme 3, compound 6c)

Compound **6c** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 6,7-dihydro-5H-benzo[7]annulen-9-yl dimethylcarbamate (46.3 mg, 0.20 mmol) and (2-methoxyphenyl)magnesium bromide (0.40 mmol, in THF) were used.

White solid (48 mg, 95%). M.P.: 72.7–74.8 °C. Eluents (R_f = 0.5, Hexane/EA = 30:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.02–2.07 (m, 2H), 2.19–2.26 (m, 2H), 2.79–2.82 (m, 2H), 3.58 (s, 3H), 6.29 (t, J = 7.1 Hz, 1H), 6.87–6.90 (m, 2H), 6.96–7.00 (m, 1H), 7.10–7.19 (m, 2H), 7.24–7.31 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 25.3, 32.3, 35.0, 55.6, 111.4, 120.4, 125.5, 126.3, 127.4, 128.3, 128.3, 129.9, 131.1, 132.6,

140.5, 141.2, 141.6, 157.3. HRMS (ESI): calcd. for $C_{18}H_{18}O$: 250.1358, found 250.1353.


1,2-Di(naphthalen-2-yl)cyclohex-1-ene (Scheme 3, compound 6d)



Compound **6d** was synthesized according to general procedure 4.3 (GP3). $Pd(OAc)_2$ (1.8 mg, 4 mol%), $IMes \cdot HCl$ (5.5 mg, 8 mol%), 2-(naphthalen-2-yl)cyclohex-1-en-1-yl dimethylcarbamate (59.1 mg, 0.20 mmol) and naphthalen-2-ylmagnesium bromide (0.40 mmol, in THF) were used.


White solid (50 mg, 75%). M.P.: 103.2–105.4 °C. Eluents (R_f = 0.3, Hexane) was used for flash column chromatography. 1H NMR (400 MHz, $CDCl_3$) δ 1.94–1.98 (m, 4H), 2.64–2.67 (m, 4H), 7.12–7.14 (m, 2H), 7.35–7.40 (m, 4H), 7.48–7.50 (m, 2H), 7.63–7.69 (m, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 23.4, 32.2, 125.2, 125.5, 126.9, 127.2, 127.4, 127.7, 128.2, 131.8, 133.2, 135.3, 141.4. HRMS (APPI): calcd. For $C_{26}H_{22}$: 334.1722, found 334.1716.

(Z)-(1-(3,5-dimethylphenyl)ethene-1,2-diyl)dibenzene (Scheme 3, compound 6e)




Compound **6e** was synthesized according to general procedure 4.3 (GP3). $Pd(OAc)_2$ (1.8 mg, 4 mol%), $IMes \cdot HCl$ (5.5 mg, 8 mol%), (Z)-1,2-diphenylvinyl dimethylcarbamate (53.5 mg, 0.20 mmol) and (3,5-dimethylphenyl)magnesium bromide (0.40 mmol, in THF) were used.

White solid (47 mg, 83%). M.P.: 122.4–123.8 °C. Eluents (R_f = 0.3, Hexane) was used for flash column chromatography. GCMS indicated > 99:1 isomer ratio. 1H NMR (400 MHz, $CDCl_3$) δ 2.31 (s, 6H), 6.88–6.90 (m, 2H), 6.98 (s, 1H), 7.01 (s, 1H), 7.10–7.21 (m, 5H), 7.30–7.41 (m, 5H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 21.3, 126.6, 127.3, 127.5, 127.8, 127.8, 127.9, 128.1, 129.0, 129.5, 137.4, 138.0, 140.2, 142.7, 143.6. HRMS (APPI): calcd. for $C_{22}H_{20}$: 284.1565, found 284.1561.


(Z)-1-methoxy-4-(1-phenylprop-1-en-1-yl)benzene (Scheme 3, compound 6f)¹⁴

Compound **6f** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), (Z)-1-phenylprop-1-en-1-yl dimethylcarbamate (41.1 mg, 0.20 mmol) and (4-methoxyphenyl)magnesium bromide (0.40 mmol, in THF) were used. Colorless liquid (43 mg, 95%). Eluents (R_f = 0.5, Hexane/EA = 19:1) was used for flash column chromatography. GCMS indicated > 99:1 isomer ratio. ¹H NMR (400 MHz, CDCl₃) δ 1.81 (d, J = 7.0 Hz, 3H), 3.86 (s, 3H), 6.13–6.18 (m, 1H), 6.93–6.95 (m, 2H), 7.13–7.15 (m, 2H), 7.21–7.30 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 15.7, 55.2, 113.5, 123.8, 126.6, 127.3, 128.0, 131.2, 132.3, 142.1, 143.4, 158.5.

4-(*p*-Tolyl)-2H-chromen-2-one (Scheme 3, compound 6g)¹⁵


Compound **6g** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), NaOtBu (3.1 mg, 16 mol%), 2-oxo-2H-chromen-4-yl dimethylcarbamate (46.6 mg, 0.20 mmol) and *p*-tolylzinc reagent (0.40 mmol, in THF) were used.

White solid (42 mg, 89%). Eluents (R_f = 0.5, Hexane/EA = 4:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.45 (s, 3H), 6.36 (s, 1H), 7.20–7.24 (m, 1H), 7.31–7.41 (m, 5H), 7.51–7.56 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.3, 114.9, 117.2, 119.0, 124.0, 127.0, 128.4, 129.5, 131.8, 132.3, 139.9, 154.2, 155.7, 160.8.

1-Methyl-4-(*p*-tolyl)quinolin-2(1*H*)-one (Scheme 3, compound **6h)¹⁶**


Compound **6h** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 1-methyl-2-oxo-1,2-dihydroquinolin-4-yl dimethylcarbamate (49.3 mg, 0.20 mmol) and *p*-tolylmagnesium bromide (0.40 mmol, in THF) were used.

Colorless liquid (39 mg, 78%). Eluents (*R*_f = 0.5, DCM/EA = 3:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.44 (s, 3H), 3.77 (s, 3H), 6.67 (s, 1H), 7.14–7.18 (m, 1H), 7.28–7.32 (m, 4H), 7.41–7.43 (m, 1H), 7.55–7.60 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.2, 29.4, 114.3, 120.5, 121.0, 121.8, 127.7, 128.8, 129.2, 130.5, 134.1, 138.5, 140.2, 150.9, 161.9.

4-(Cyclohept-1-en-1-yl)-1,1'-biphenyl (Scheme 3, compound **6i)¹⁷**


Compound **6i** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), cyclohept-1-en-1-yl dimethylcarbamate (36.7 mg, 0.20 mmol) and [1,1'-biphenyl]-4-ylmagnesium bromide (0.40 mmol, in THF) were used.

White solid (45 mg, 90%). Eluents (*R*_f = 0.5, Hexane/DCM = 19:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 1.60–1.64 (m, 2H), 1.70–1.74 (m, 2H), 1.87–1.91 (m, 2H), 2.34–2.38 (m, 2H), 2.68–2.70 (m, 2H), 6.21 (t, *J* = 6.7 Hz, 1H), 7.35–7.38 (m, 1H), 7.43–7.50 (m, 4H), 7.56–7.58 (m, 2H), 7.63–7.65 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 26.8, 26.9, 28.9, 32.6, 32.8, 126.0, 126.8, 126.9, 127.0, 128.7, 130.5, 139.1, 140.9, 143.8, 144.5.

1-(3-Methoxyphenyl)cyclohept-1-ene (Scheme 3, compound 6j)¹⁸


Compound **6j** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), cyclohept-1-en-1-yl dimethylcarbamate (36.7 mg, 0.20 mmol) and (3-methoxyphenyl)magnesium bromide (0.40 mmol, in THF) were used.

Colorless liquid (40 mg, 98%). Eluents (R_f = 0.5, Hexane/EA = 9:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 1.55–1.61 (m, 2H), 1.64–1.69 (m, 2H), 1.83–1.89 (m, 2H), 2.29–2.33 (m, 2H), 2.61–2.64 (m, 2H), 3.83 (s, 3H), 6.13 (t, J = 6.7 Hz, 1H), 6.77–6.79 (m, 1H), 6.88–6.90 (m, 1H), 6.93–6.95 (m, 1H), 7.21–7.23 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 26.7, 26.9, 28.8, 32.7, 32.8, 55.1, 111.5, 111.5, 118.2, 129.0, 130.5, 144.8, 146.5, 159.4.


4'-Methoxy-2,3,4,5-tetrahydro-1,1'-biphenyl (Scheme 3, compound 6k)¹⁹

Compound **6k** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), cyclohex-1-en-1-yl dimethylcarbamate (33.8 mg, 0.20 mmol) and (4-methoxyphenyl)magnesium bromide (0.40 mmol, in THF) were used.

White solid (32 mg, 85%). Eluents (R_f = 0.5, Hexane/EA = 9:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 1.64–1.70 (m, 2H), 1.76–1.82 (m, 2H), 2.20–2.22 (m, 2H), 2.38–2.41 (m, 2H), 3.81 (s, 3H), 6.03–6.06 (m, 1H), 6.85–6.87 (m, 2H), 7.32–7.34 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 22.2, 23.1, 25.8, 27.4, 55.2, 113.5, 123.1, 125.9, 135.3, 135.9, 158.4.


***N,N*-dimethyl-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-amine (Scheme 3, compound 6l)²⁰****6l**

Compound **6l** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), cyclohex-1-en-1-yl dimethylcarbamate (33.8 mg, 0.20 mmol) and (4-(dimethylamino)phenyl)magnesium bromide (0.40 mmol, in THF) were used. Pale yellow solid (33 mg, 82%). Eluents (*R*_f = 0.4, Hexane/EA = 19:1) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 1.64–1.70 (m, 2H), 1.77–1.82 (m, 2H), 2.19–2.24 (m, 2H), 2.39–2.43 (m, 2H), 2.96 (s, 6H), 6.02–6.04 (m, 1H), 6.71–6.74 (m, 2H), 7.30–7.34 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 22.3, 23.2, 25.8, 27.3, 40.7, 112.5, 121.5, 125.5, 131.2, 135.9, 149.5.

3-(4-Fluorophenyl)-1,2-dihydronaphthalene (Scheme 3, compound 6m)⁶**6m**


Compound **6m** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-2-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and (4-fluorophenyl)magnesium bromide (0.40 mmol, in THF) were used. White solid (42 mg, 93%). Eluents (*R*_f = 0.4, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.71–2.75 (m, 2H), 2.95–2.99 (m, 2H), 6.80 (s, 1H), 7.04–7.10 (m, 2H), 7.13–7.22 (m, 4H), 7.49–7.54 (m, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ –114.9; ¹³C NMR (100 MHz, CDCl₃) δ 26.4, 28.1, 115.3 (d, *J* = 21.2 Hz), 124.1, 124.2, 126.6 (d, *J* = 8.1 Hz), 126.64, 126.7, 127.0, 127.2, 134.6, 137.2 (d, *J* = 3.3 Hz), 137.6, 162.2 (d, *J* = 245.3 Hz).

Alkenyl pivalate as electrophile: according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-Dihydronaphthalen-2-yl pivalate²¹ (46.0 mg, 0.20 mmol) and (4-fluorophenyl)magnesium bromide (0.40 mmol, in THF) were used to afford **6m** as white solid (42 mg, 93%).


3-(3,4-Dihydronaphthalen-2-yl)benzo[*b*]thiophene (Scheme 3, compound **6n)²²**

Compound **6n** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-2-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and benzo[*b*]thiophen-3-ylmagnesium bromide (0.40 mmol, in THF) were used.


White solid (30 mg, 57%). Eluents (*R*_f = 0.2, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 2.84 (t, *J* = 8.2 Hz, 2H), 3.04 (t, *J* = 8.2 Hz, 2H), 6.92 (s, 1H), 7.16–7.24 (m, 4H), 7.39–7.47 (m, 3H), 7.92 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 2.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 28.2, 28.4, 122.3, 123.0, 123.4, 124.2, 124.3, 126.0, 126.5, 126.6, 127.0, 127.4, 134.4, 134.4, 134.8, 137.4, 138.6, 140.7.

3-(*p*-Tolyl)-1,2-dihydronaphthalene (Scheme 3, compound **6o)⁶**

A Schlenk tube was charged with Teflon-coated magnetic stir bar, Pd(OAc)₂ (2.2 mg) and IMes•HCl (6.8 mg), and then was evacuated and flushed with nitrogen (3 cycles). Freshly distilled THF (5.00 mL) was added by a syringe and the mixture was stirred at room temperature for 10 min to afford the stock solution (0.50 mol% of Pd / 0.50 mL). To another Schlenk tube was added 3,4-dihydronaphthalen-2-yl dimethylcarbamate (43.5 mg, 0.20 mmol). This tube was evacuated and flushed with nitrogen (3 cycles). Stock solution (0.50 mL, 0.50 mol% of Pd) was transferred to this Schlenk tube followed by the addition of *p*-tolylmagnesium bromide (0.40 mmol, in THF). The mixture was stirred at room temperature for 1 h. According to general procedure 4.3 (GP3), the following work-up afforded the product **6o** as a white solid (41 mg, 93%). *R*_f = 0.55 (Hexane). ¹H NMR (400 MHz, CDCl₃) δ 2.42 (s, 3H), 2.79 (t, *J* = 8.1 Hz, 2H), 3.00 (t, *J* = 8.1 Hz, 2H), 6.88 (s, 1H), 7.16–7.26 (m, 6H), 7.49–7.51 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 26.3, 28.2, 123.5, 125.0, 126.4, 126.5, 126.7, 127.1, 129.1, 134.7, 134.8, 137.1, 138.1, 138.5.


3-(4-(*tert*-Butyl)phenyl)-1,2-dihydronaphthalene (Scheme 3, compound 6p)⁶

A Schlenk tube was charged with Teflon-coated magnetic stir bar, Pd(OAc)₂ (2.2 mg) and IMes•HCl (6.8 mg), and then was evacuated and flushed with nitrogen (3 cycles). Freshly distilled THF (5.00 mL) was added by a syringe and the mixture was stirred at room temperature for 10 min to afford the stock solution (0.50 mol% of Pd / 0.50 mL). To another Schlenk tube was added 3,4-dihydronaphthalen-2-yl dimethylcarbamate (43.5 mg, 0.20 mmol). This tube was evacuated and flushed with nitrogen (3 cycles). Upper clean stock solution (0.50 mL, 0.50 mol% of Pd) was transferred to this Schlenk tube followed by the addition of (4-(*tert*-butyl)phenyl)magnesium bromide (0.4 mmol, in THF). The mixture was stirred at room temperature for 1 h. According to general procedure 4.3 (GP3), the following work-up afforded the product **6p** as a white solid (49 mg, 93%). *R*_f = 0.35 (Hexane). ¹H NMR (400 MHz, CDCl₃) δ 1.39 (s, 9H), 2.79 (t, *J* = 8.0 Hz, 2H), 2.99 (t, *J* = 8.0 Hz, 2H), 6.90 (s, 1H), 7.16–7.26 (m, 4H), 7.44–7.46 (m, 2H), 7.54–7.56 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 26.2, 28.2, 31.3, 34.5, 123.6, 124.8, 125.4, 126.5, 126.5, 126.8, 127.2, 134.7, 134.9, 138.1, 138.4, 150.4.

4-Hexyl-1,2-dihydronaphthalene (Scheme 4, compound 9a)²³


Compound **9a** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and hexylmagnesium bromide (0.40 mmol, in THF) were used.

Colorless liquid (38 mg, 88%). Eluents (*R*_f = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 0.91–0.94 (m, 3H), 1.30–1.43 (m, 6H), 1.52–1.59 (m, 2H), 2.24–2.29 (m, 2H), 2.43–2.48 (m, 2H), 2.74–2.78 (m, 2H), 5.87 (t, *J* = 4.5 Hz, 1H), 7.14–7.16 (m, 2H), 7.20–7.24 (m, 1H), 7.27–7.29 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 22.7, 23.1, 28.4, 28.5, 29.3, 31.7, 32.8, 122.6, 124.5, 126.2, 126.4, 127.5, 135.1, 136.6, 136.8.

((3,4-Dihydronaphthalen-1-yl)methyl)trimethylsilane (Scheme 4, compound 9b)²⁴


Compound **9b** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and ((trimethylsilyl)methyl)magnesium chloride (0.40 mmol, in THF) were used.

Colorless liquid (34 mg, 79%). Eluents (*R*_f = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 0.01 (s, 9H), 1.96 (s, 2H), 2.24–2.29 (m, 2H), 2.74–2.78 (m, 2H), 5.72 (t, *J* = 4.6 Hz, 1H), 7.12–7.25 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ –1.1, 22.3, 23.2, 28.9, 122.7, 123.4, 125.9, 126.4, 127.3, 134.2, 135.8, 136.8.

4-Cyclopropyl-1,2-dihydronaphthalene (Scheme 4, compound 9c)²⁵

Compound **9c** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and cyclopropylmagnesium bromide (0.40 mmol, in THF) were used.


Colorless liquid (24 mg, 70%). Eluents (*R*_f = 0.5, Hexane) was used for flash column chromatography. ¹H NMR (400 MHz, CDCl₃) δ 0.50–0.54 (m, 2H), 0.79–0.83 (m, 2H), 1.62–1.69 (m, 1H), 2.24–2.30 (m, 2H), 2.74–2.78 (m, 2H), 5.81–5.84 (m, 1H), 7.15–7.20 (m, 2H), 7.24–7.28 (m, 1H), 7.66–7.68 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 5.2, 13.1, 23.0, 28.1, 123.1, 123.2, 126.2, 126.6, 127.2, 135.9, 136.2, 137.5.

3-Cyclopentyl-1,2-dihydronaphthalene (Scheme 4, compound 9d)

Compound **9d** was synthesized according to general procedure 4.3 (GP3). Pd(OAc)₂ (1.8 mg,


4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-2-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and cyclopentylmagnesium bromide (0.40 mmol, in THF) were used. Colorless liquid (33 mg, 83%). Eluents (R_f = 0.6, Hexane) was used for flash column chromatography. ^1H NMR (400 MHz, CDCl_3) δ 1.48–1.57 (m, 2H), 1.61–1.79 (m, 4H), 1.84–1.91 (m, 2H), 2.26–2.30 (m, 2H), 2.59–2.67 (m, 1H), 2.80–2.84 (m, 2H), 6.28 (s, 1H), 7.01–7.02 (m, 1H), 7.07–7.17 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.3, 25.9, 28.4, 31.0, 47.1, 120.3, 125.3, 125.9, 126.3, 127.0, 134.6, 135.1, 145.5. HRMS (APPI): calcd. for $\text{C}_{15}\text{H}_{18}$: 198.1409, found 198.1404.

3-Cyclohexyl-1,2-dihydronaphthalene (Scheme 4, compound **9e**)²⁶



Compound **9e** was synthesized according to general procedure 4.3 (GP3). $\text{Pd}(\text{OAc})_2$ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-2-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and cyclohexylmagnesium chloride (0.40 mmol, in THF) were used. Colorless liquid (38 mg, 89%). Eluents (R_f = 0.6, Hexane) was used for flash column chromatography. ^1H NMR (400 MHz, CDCl_3) δ 1.19–1.42 (m, 5H), 1.74–1.77 (m, 1H), 1.83–1.87 (m, 4H), 2.05–2.10 (m, 1H), 2.26–2.30 (m, 2H), 2.79–2.83 (m, 2H), 6.23 (s, 1H), 7.01–7.18 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 26.0, 26.4, 26.6, 28.4, 31.5, 45.4, 120.1, 125.4, 125.9, 126.3, 127.0, 134.7, 135.1, 147.5.


4-(prop-1-en-2-yl)-1,2-dihydronaphthalene (Scheme 4, compound **9f**)²⁷



Compound **9f** was synthesized according to general procedure 4.3 (GP3). $\text{Pd}(\text{OAc})_2$ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%), 3,4-dihydronaphthalen-1-yl dimethylcarbamate (43.5 mg, 0.20 mmol) and prop-1-en-2-ylmagnesium bromide (0.40 mmol, in THF) were used. Colorless liquid (21 mg, 62%). Eluents (R_f = 0.5, Hexane) was used for flash column chromatography. ^1H NMR (400 MHz, CDCl_3) δ 1.98 (s, 3H), 2.26–2.30 (m, 2H), 2.74–2.78 (m, 2H), 5.03–5.05 (m, 1H), 5.10–5.12 (m, 1H), 6.00 (t, J = 4.7 Hz, 1H), 7.14–7.24 (m, 4H);

^{13}C NMR (100 MHz, CDCl_3) δ 22.8, 23.1, 28.3, 114.4, 124.9, 125.1, 126.2, 126.7, 127.5, 133.9, 136.8, 141.5, 144.5.


Tamoxifen, (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine (Scheme 6, compound 11a)



To a dry Schlenk tube was charged with Teflon-coated magnetic stir bar (5 mm \times 10 mm), $\text{Pd}(\text{OAc})_2$ (4.5 mg, 10 mol%), $\text{IMes} \cdot \text{HCl}$ (13.6 mg, 20 mol%) and (Z)-1,2-diphenylbut-1-en-1-yl dimethylcarbamate **10a** (59.1 mg, 0.20 mmol). Then the tube was evacuated and flushed with nitrogen (3 cycles). The freshly distilled THF (0.40 mL) was added followed by the addition of (4-(2-(dimethylamino)ethoxy)phenyl)magnesium bromide²⁸ (0.40 mmol, in THF). The Schlenk tube was sealed and magnetically stirred at oil bath (50 $^\circ\text{C}$) for 24 h. When cooled down to room temperature, water (\sim 4 mL) were added to quench the reaction, the mixture was extracted with EA and the organic layer was combined. After removing the solvent, the residue was subjected to column chromatography ($\text{DCM}/\text{MeOH} = 96:4$)²⁹ to afford (Z)-Tamoxifen **11a** (46 mg, 62%), 99% (Z)-isomer.


^1H NMR (400 MHz, CDCl_3) δ 0.93 (t, $J = 7.4$ Hz, 3H), 2.29 (s, 6H), 2.46 (q, $J = 7.4$ Hz, 2H), 2.66 (t, $J = 5.8$ Hz, 2H), 3.94 (t, $J = 5.8$ Hz, 2H), 6.57 (q, $J = 8.7$ Hz, 2H), 6.78 (q, $J = 8.7$ Hz, 2H), 7.09–7.20 (m, 5H), 7.24–7.29 (m, 3H), 7.33–7.37 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.6, 29.0, 45.8, 58.2, 65.6, 113.3, 126.0, 126.5, 127.8, 128.0, 129.4, 129.7, 131.8, 135.5, 138.2, 141.3, 142.4, 143.8, 156.7. The spectral data is in accordance with literature.³⁰


(E)-Tamoxifen, (E)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine (Scheme 6, compound 11b)




To a dry Schlenk tube was charged with Teflon-coated magnetic stir bar (5 mm × 10 mm), Pd(OAc)₂ (1.8 mg, 4 mol%), IMes•HCl (5.5 mg, 8 mol%) and (*E*)-1,2-diphenylbut-1-en-1-yl dimethylcarbamate **10b** (59.1 mg, 0.20 mmol). Then the tube was evacuated and flushed with nitrogen (3 cycles). The freshly distilled THF (0.40 mL) was added followed by the addition of (4-(2-(dimethylamino)ethoxy)phenyl)magnesium bromide (0.40 mmol, in THF). The Schlenk tube was sealed and magnetically stirred at oil bath (50 °C) for 18 h. Similar following work-up gave (*E*)-Tamoxifen **11b** (52 mg, 70%), 99% (*E*)-isomer.


¹H NMR (400 MHz, CDCl₃) δ 0.95 (t, *J* = 7.4 Hz, 3H), 2.36 (s, 6H), 2.51 (q, *J* = 7.4 Hz, 2H), 2.75 (t, *J* = 5.8 Hz, 2H), 4.09 (t, *J* = 5.8 Hz, 2H), 6.87–6.91 (m, 4H), 6.97–7.02 (m, 3H), 7.07–7.17 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 13.5, 29.0, 45.9, 58.3, 65.9, 114.1, 125.6, 126.0, 127.2, 127.7, 129.7, 130.5, 130.8, 136.0, 138.4, 141.9, 142.4, 143.3, 157.5. The spectral data is in accordance with literature.³⁰



7. ^1H , ^{13}C , ^{19}F -NMR and HRMS spectra







Mass	Calc. Mass	mDa	PPM	Formula
254.1158	254.1151	-0.65	-2.81	C ₁₄ H ₁₇ NO ₂ Na









Mass	Calc. Mass	mDa	PPM	Formula
228.1001	228.0995	-0.6	-2.93	C ₁₂ H ₁₅ NO ₂ Na










Mass	Calc. Mass	mDa	PPM	Formula
296.1653	296.1645	-0.79	-2.69	C ₁₉ H ₂₂ NO ₂










Mass	Calc. Mass	mDa	PPM	Formula
206.1156	206.1151	-0.45	-2.46	C ₁₀ H ₁₇ NO ₂ Na










Mass	Calc. Mass	mDa	PPM	Formula
296.1647	296.1645	-0.19	-0.66	C ₁₉ H ₂₂ NO ₂










Mass	Calc. Mass	mDa	PPM	Formula
296.1646	296.1645	-0.09	-0.32	C ₁₉ H ₂₂ NO ₂











Mass	Calc. Mass	mDa	PPM	Formula
248.1561	248.1565	0.4	1.61	C ₁₉ H ₂₀















Mass	Calc. Mass	mDa	PPM	Formula
262.1717	262.1722	0.45	1.72	C ₂₀ H ₂₂










Mass	Calc. Mass	mDa	PPM	Formula
248.1559	248.1565	0.6	2.42	C ₁₉ H ₂₀











Mass	Calc. Mass	mDa	PPM	Formula
286.1353	286.1358	0.47	1.63	C ₂₁ H ₁₈ O















Mass	Calc. Mass	mDa	PPM	Formula
298.1717	298.1722	0.45	1.51	C ₂₃ H ₂₂











Mass	Calc. Mass	mDa	PPM	Formula
320.1561	320.1565	0.4	1.25	C ₂₅ H ₂₀
















Mass	Calc. Mass	mDa	PPM	Formula
294.1404	294.1409	0.45	1.53	C ₂₃ H ₁₈


















Mass	Calc. Mass	mDa	PPM	Formula
238.1151	238.1158	0.68	2.85	C ₁₇ H ₁₅ F










Mass	Calc. Mass	mDa	PPM	Formula
250.1353	250.1358	0.47	1.86	C ₁₈ H ₁₈ O










Mass	Calc. Mass	mDa	PPM	Formula
334.1716	334.1722	0.55	1.65	C ₂₆ H ₂₂











Mass	Calc. Mass	mDa	PPM	Formula
284.1561	284.1565	0.4	1.41	C ₂₂ H ₂₀

































































































Mass	Calc. Mass	mDa	PPM	Formula
198.1404	198.1409	0.45	2.27	C ₁₅ H ₁₈




















8. References

- (1) Armarego, W. L. F.; Perrin, D. D. In *Purification of Laboratory Chemicals*, Ed. 6; Armarego, W.L.F., Chai, C.L.L., Eds.; Butterworth-Heinemann: Oxford, **2009**; pp 88–444.
- (2) Liu, E.-C.; Chen, M.-K.; Li, J.-Y.; Wu, Y.-T. *Chem. Eur. J.* **2015**, *21*, 4755–4761.
- (3) Love, B. E.; Jones, E. G. *J. Org. Chem.* **1999**, *64*, 3755–3756.
- (4) Kinuta, H.; Hasegawa, J.; Tobisu, M.; Chatani, N. *Chemistry Letters* **2015**, *44*, 366–368.
- (5) Julienne, D.; Delacroix, O.; Gaumont, A.-C. *Phosphorus Sulfur Silicon Relat. Elem.* **2009**, *184*, 846–856.
- (6) Xu, L.; Li, B.-J.; Wu, Z.-H.; Lu, X.-Y.; Guan, B.-T.; Wang, B.-Q.; Zhao, K.-Q.; Shi, Z.-J. *Org. Lett.* **2010**, *12*, 884–887.
- (7) Stadlbauer, W.; Moser, C. V. Synthesis of heterocyclic carbamates with potential activity in plant protection. In *The 17th International Electronic Conference on Synthetic Organic Chemistry*, MDPI AG: Basel, Switzerland, 2013, pp a027/021–a027/011.
- (8) Liao, L.-L.; Gui, Y.-Y.; Zhang, X.-B.; Shen, G.; Liu, H.-D.; Zhou, W.-J.; Li, J.; Yu, D.-G. *Org. Lett.* **2017**, *19*, 3735–3738.
- (9) Jolliffe, J. D.; Armstrong, R. J.; Smith, M. D. *Nat. Chem.* **2017**, *9*, 558–562.
- (10) Barluenga, J.; Florentino, L.; Aznar, F.; Valdés, C. *Org. Lett.* **2011**, *13*, 510–513.
- (11) Choi, D. S.; Kim, J. H.; Shin, U. S.; Deshmukh, R. R.; Song, C. E. *Chem. Commun.* **2007**, 3482–3484.
- (12) Zhao, X.; Wu, G.; Yan, C.; Lu, K.; Li, H.; Zhang, Y.; Wang, J. *Org. Lett.* **2010**, *12*, 5580–5583.
- (13) Qu, B.; Samankumara, L. P.; Ma, S.; Fandrick, K. R.; Desrosiers, J.-N.; Rodriguez, S.; Li, Z.; Haddad, N.; Han, Z. S.; McKellop, K.; Pennino, S.; Grinberg, N.; Gonnella, N. C.; Song, J. J.; Senanayake, C. H. *Angew. Chem. Int. Ed.* **2014**, *53*, 14428–14432.
- (14) Zhu, G.; Kong, W.; Feng, H.; Qian, Z. *J. Org. Chem.* **2014**, *79*, 1786–1795.
- (15) Wong, P. Y.; Chow, W. K.; Chung, K. H.; So, C. M.; Lau, C. P.; Kwong, F. Y. *Chem. Commun.* **2011**, *47*, 8328–8330.
- (16) Xing, C.-H.; Lee, J.-R.; Tang, Z.-Y.; Zheng, J. R.; Hu, Q.-S. *Adv. Synth. Catal.* **2011**, *353*, 2051–2059.
- (17) Delorme, D.; Woo, S. H.; Vaisburg, A. Preparation of Hydroxamic Acids as Inhibitors of Histone Deacetylase, WO 2001070675A2, 2001.
- (18) Ackermann, L.; Kapdi, A. R.; Fenner, S.; Kornhaaß, C.; Schulzke, C. *Chem. Eur. J.* **2011**, *17*, 2965–2971.

- (19) Liu, E.-C.; Topczewski, J. J. *J. Am. Chem. Soc.* **2019**, *141*, 5135–5138.
- (20) Zhang, X.-Q.; Wang, Z.-X. *Synlett* **2013**, *24*, 2081–2084.
- (21) Li, B. -J.; Wu, Z. -H.; Guan, B. -T.; Sun, C. -L.; Wang, B. -Q.; Shi, Z. -J. *J. Am. Chem. Soc.* **2009**, *131*, 14656-14657.
- (22) Murthy, T. S.; Tilak, B. D., Thiophenes and thiapyrans. XXIV. Cyclodehydration of aroylmethyl aryl sulfides. *J. Sci. Ind. Res.* **1960**, *19B*, 395-401.
- (23) Nattmann, L.; Lutz, S.; Ortsack, P.; Goddard, R.; Cornella, J. *J. Am. Chem. Soc.* **2018**, *140*, 13628–13633.
- (24) Guo, L.; Leiendecker, M.; Hsiao, C.-C.; Baumann, C.; Rueping, M. *Chem. Commun.* **2015**, *51*, 1937–1940.
- (25) Wang, Y.-L.; Zhang, W.-M.; Dai, J.-J.; Feng, Y.-S.; Xu, H.-J. *RSC Adv.* **2014**, *4*, 61706–61710.
- (26) Gutsche, C. D.; Saha, N. N.; Johnson, H. E. *J. Am. Chem. Soc.* **1957**, *79*, 4441–4448.
- (27) Juo, R. R.; Herz, W. *J. Org. Chem.* **1985**, *50*, 700–703.
- (28) Hanna, L. E.; Konev, M. O.; Jarvo, E. R. *Eur. J. Org. Chem.* **2019**, *2019*, 184–187.
- (29) Heijnen, D.; van Zuijlen, M.; Tosi, F.; Feringa, B. L. *Org. Biomol. Chem.* **2019**, *17*, 2315–2320.
- (30) Itami, K.; Kamei, T.; Yoshida, J.-i. *J. Am. Chem. Soc.* **2003**, *125*, 14670–14671.